Arrhythmias, Cardiac  >>  rivaroxaban  >>  Phase 3
Welcome,         Profile    Billing    Logout  

6 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
rivaroxaban / Generic mfg.
NCT00494871: Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation

Completed
3
1280
Japan
Rivaroxaban (Xarelto, BAY59-7939), Warfarin, Rivaroxaban placebo, Warfarin placebo
Bayer, Janssen R&D, L.L.C.
Atrial Fibrillation
12/09
01/10
ROCKET AF, NCT00403767 / 2006-004595-13: An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation

Checkmark ROCKET AF
Oct 2013 - Oct 2013: ROCKET AF
Checkmark ROCKET AF: Efficacy of rivaroxaban compared with warfarin
Jun 2013 - Jun 2013: ROCKET AF: Efficacy of rivaroxaban compared with warfarin
Completed
3
14269
Europe, Canada, US, RoW
Rivaroxaban, Warfarin, Matching placebo for Rivaroxaban arm (Warfarin placebo), Matching placebo for Warfarin arm (Rivaroxaban placebo)
Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Bayer
Atrial Fibrillation, Stroke, Embolism
09/10
09/10
X-VERT, NCT01674647 / 2011-002234-39: Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Completed
3
1504
US, Canada, Europe, RoW
Rivaroxaban (Xarelto, BAY59-7939), Vitamin K antagonist (VKA)
Bayer, Janssen Research & Development, LLC
Atrial Fibrillation
01/14
01/14
VENTURE-AF, NCT01729871 / 2012-001484-79: A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy

Completed
3
253
US, Europe
rivaroxaban, uninterrupted vitamin K antagonist (VKA)
Janssen Scientific Affairs, LLC, Bayer
Atrial Fibrillation
10/14
10/14
NCT01839357 / 2012-001062-15: Exploring the Efficacy of Once Daily Oral Rivaroxaban for Treatment of Thrombus in Left Atrial/Left Atrial Appendage in Subjects With Nonvalvular Atrial Fibrillation or Atrial Flutter

Completed
3
60
Europe, RoW
Rivaroxaban (Xarelto, BAY59-7939)
Bayer, Janssen Research & Development, LLC
Atrial Fibrillation
11/14
12/14
PIONEER AF-PCI, NCT01830543 / 2012-001491-11: A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

Completed
3
2124
US, Canada, Europe, RoW
rivaroxaban 2.5 mg, rivaroxaban 15 mg, rivaroxaban 10 mg, aspirin (ASA), vitamin K antagonist (VKA), clopidogrel, prasugrel, ticagrelor
Janssen Scientific Affairs, LLC, Bayer
Atrial Fibrillation, Percutaneous Coronary Intervention
07/16
07/16

Download Options